ࡱ> #`bjbjmm .%n n n  """8"#d g#$"%%%'&'&'&fffffff$ih\l#gun q(#&'&q(q(#g%%g]4]4]4q( R%n %mb]4q(f]4]4[DL "n _%# CHP"1\&qag0g\dm3dmL__^dmn y`'&v&T]4&D5'<'&'&'&#g#g3^'&'&'&gq(q(q(q( $" "   Thrombotic Thrombocytopenic Purpura the Role of ADAMTS13 Assay in Clinical Practice Running title: ADAMTS13 in clinical practice Nadira Durakovic, Radovan Radonic, Vladimir Gasparovic Department of Internal medicine, Divisions of Intensive Care Medicine and Hematology, Clinical Hospital Center Zagreb, Zagreb, Croatia ABSTRACT Thrombotic thrombocytopenic purpura (TTP) is a disorder characterized by disseminated thrombotic occlusions of the microcirculation. Identification of ADAMTS13 protease and its place in the pathophysiology of TTP led to better understanding of the disease and better survival for the diseased. Here we show a case report of a patient that had a normal ADAMTS13 protease activity and an unusual clinical presentation and utilize that case to highlight how the absence of a severe ADAMTS13 protease deficiency does not preclude a diagnosis of TTP and how early initiation and continuation of plasma exchange therapy can lead to a positive outcome, even in a severely ill patient. Even though ADAMTS13 protease determination has no immediate influence on the decision whether or not to start the plasma exchange therapy, it has great impact on future management of the patient and should be determined whenever possible. Key words Thrombotic thrombocytopenic purpura, ADAMTS13 protease, plasma exchange therapy Introduction Thrombotic thrombocytopenic purpura (TTP) was first described by Moschcowitz in 1924. It is a disease characterized by disseminated thrombotic occlusions of the microcirculation, clinically described as being distinguished by a pentad of symptoms: microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, fever and renal dysfunction. However, lately fewer patients are described presenting with fever and severe neurological symptoms ADDIN EN.CITE Vesely20033317Vesely, Sara K.George, James N.Lammle, BernhardStudt, Jan-DirkAlberio, LorenzoEl-Harake, Mayez A.Raskob, Gary E.ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsBloodBlood60-6810212003July 1, 2003http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;102/1/60 10.1182/blood-2003-01-01931, which is probably due to the early start of treatment, shown to be crucial for the success of the therapy. Until 1991 the mortality of TTP was around 90% ADDIN EN.CITE Amorosi EL19664417Amorosi EL, Ultmann JEThrombotic thrombocytopenic purpura: report of 16 cases and review of the literatureMedicineMedicine139-1594519662, and there were just anecdotal evidence that plasma infusions might improve chances of survival in these patients. A pivotal study was done by the Canadian Apheresis Study Group that showed superiority of plasma exchange therapy over plasma infusion, with overall mortality of 29% in both groups, mortality in plasma exchange group being 21% ADDIN EN.CITE Rock GA19915517Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RAComparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study GroupN Engl J MedN Engl J Med393-7325619913. Pathogenesis of the disease was unknown until 1997, when acquired antibodies were first identified in adults with TTP that inhibit von Willebrand factor (vWF) cleaving protease, which is normally found in plasma and is responsible for cleaving large multimeres of vWF that are otherwise capable of agglutinating circulating platelets ADDIN EN.CITE Furlan M1998 6617Furlan M, Robles R, Gallbusera M et al.von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromeN Engl J MedN Engl J Med1578-84339221998 Tsai HM19987717Tsai HM, Lian ECAntibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J MedN Engl J Med1585-943392219984, 5. It was also found that there is a subset of patients with familiar thrombotic thrombocytopenic purpura that lacked vWF-cleaving protease activity but had no inhibitor. In 2001 vWF-cleaving protease was purified and cloned, it was shown to be a new member of the a disintegrin and metalloprotease with thrombospondin type 1 repeats family, and named ADAMTS13 protease ADDIN EN.CITE Fujikawa20019917Fujikawa, KazuoSuzuki, HiroshiMcMullen, BradChung, DominicPurification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase familyBloodBlood1662-16669862001September 15, 2001http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;98/6/1662 10.1182/blood.V98.6.1662Gerritsen20018817Gerritsen, Helena E.Robles, RodolfoLammle, BernhardFurlan, MihaPartial amino acid sequence of purified von Willebrand factor-cleaving proteaseBloodBlood1654-16619862001September 15, 2001http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;98/6/1654 10.1182/blood.V98.6.1654Levy GG2001101017Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura NatureNature488-4944132001Soejima K2001111117Soejima K, Mimura N, Hirashima M, et alA novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J BiochemJ Biochem475-4801302001Zheng X2001121217Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa KStructure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura J Biol ChemJ Biol Chem41059-4106327620016-10. There was a lot of excitement generated, because now pathogenesis of TTP could finally be explained: autoantibodies are generated against ADAMTS13 protease, and the absence of ADAMTS13 protease activity allows VWF and platelets to accumulate in microvascular thrombi, which leads to platelet consumption, hemolysis, and microvascular occlusion, leading to infarction damage of brain and kidney. Plasma exchange is efficacious because it removes pathogenic autoantibodies and replenishes the missing ADAMTS13 protease, restoring the normal regulation of VWF-dependent platelet adhesion. However, reality proved not to be as simple. In the following years a lot of studies were done looking into activity of ADAMTS13 protease in various populations and their response to plasma exchange therapy ADDIN EN.CITE Gasparovic V2000141417Gasparovic V, Radonic R, Mejic S et al. Possibilities and limits of treatment in patients with thrombotic thrombocytopenic purpuraIntensive Care MedIntensive Care Med1690-326112000Kremer Hovinga JA2004151517Kremer Hovinga JA, Studt JD, Alberio L, Lmmle B.von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experienceSemin HematolSemin Hematol75- 82412004Studt JD2004131317Studt JD, Kremer Hovinga JA, Radonic R et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twinsBlood Blood4195-97103 112004Veyradier A2001161617Veyradier A, Obert B, Houllier A, Meyer D, Girma JPSpecific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases BloodBlood1765-177298200111-14. Studies have confirmed the specificity of severe ADAMTS13 protease deficiency (< 5%) for idiopathic TTP, but sensitivity remains controversial. Severe ADAMTS13 deficiency is rare in secondary TTP, associated with hematopoietic stem cell transplantation, cancer, pregnancy, systemic infections, drug toxicity, or other predisposing conditions, and it was not shown in diarrhea-associated hemolytic uremic syndrome (HUS) caused by Shiga toxinproducing E. coli ADDIN EN.CITE Kremer Hovinga JA2004151517Kremer Hovinga JA, Studt JD, Alberio L, Lmmle B.von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experienceSemin HematolSemin Hematol75- 82412004Vesely20033317Vesely, Sara K.George, James N.Lammle, BernhardStudt, Jan-DirkAlberio, LorenzoEl-Harake, Mayez A.Raskob, Gary E.ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsBloodBlood60-6810212003July 1, 2003http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;102/1/60 10.1182/blood-2003-01-01931, 12. In that respect, determination of ADAMTS13 protease deficiency rules out the possibility of secondary TTP, and proves beyond suspicion the diagnosis of idiopathic TTP. However, the incidence of severe ADAMTS13 protease deficiency in patients with idiopathic TTP has varied from 33% to 100% in different studies ADDIN EN.CITE Furlan M1998 6617Furlan M, Robles R, Gallbusera M et al.von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromeN Engl J MedN Engl J Med1578-84339221998 Tsai HM19987717Tsai HM, Lian ECAntibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J MedN Engl J Med1585-94339221998Vesely20033317Vesely, Sara K.George, James N.Lammle, BernhardStudt, Jan-DirkAlberio, LorenzoEl-Harake, Mayez A.Raskob, Gary E.ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsBloodBlood60-6810212003July 1, 2003http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;102/1/60 10.1182/blood-2003-01-0193Veyradier A2001161617Veyradier A, Obert B, Houllier A, Meyer D, Girma JPSpecific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases BloodBlood1765-17729820011, 4, 5, 14. Furthermore, even patients with shown severe ADAMTS13 protease deficiency can achieve clinical responses with plasma exchange therapy despite persistent low ADAMTS13 protease activity ADDIN EN.CITE Bhm M2005181817Bhm M, Betz C, Miesbach W, et al The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristineBr J HaematolBr J Haematol644-652129200515. It is important to emphasize that patients regardless of their ADAMTS13 protease activity status will equally respond to plasma exchange therapy ADDIN EN.CITE Vesely20033317Vesely, Sara K.George, James N.Lammle, BernhardStudt, Jan-DirkAlberio, LorenzoEl-Harake, Mayez A.Raskob, Gary E.ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsBloodBlood60-6810212003July 1, 2003http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;102/1/60 10.1182/blood-2003-01-01931. A difference in early response to therapy and survival between two groups has not yet been shown, but there is evidence that severe ADAMTS13 protease deficiency and high antibody titers are associated with delayed response to plasma exchange therapy and increased risk of relapse ADDIN EN.CITE Bhm M2005181817Bhm M, Betz C, Miesbach W, et al The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristineBr J HaematolBr J Haematol644-6521292005Coppo P2006191917Coppo P, Wolf M, Veyradier A, et alPrognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpuraBr J HaematolBr J Haematol66-741322006Tsai HM2001202017Tsai HM, Li A, Rock G.Inhibitors of von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpuraClin LabClin Lab387-392472001Zheng XL2004171717Zheng XL, Kaufman RM, Goodnough LT, Sadler JEEffect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpuraBloodBlood4043-4049103200415-18. Relapse is frequent in TTP, rates about 30-35%, but there has been shown statistically significant difference in the frequency of relapses in the patients with severe ADAMTS13 deficiency. ADDIN EN.CITE Vesely20033317Vesely, Sara K.George, James N.Lammle, BernhardStudt, Jan-DirkAlberio, LorenzoEl-Harake, Mayez A.Raskob, Gary E.ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsBloodBlood60-6810212003July 1, 2003http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;102/1/60 10.1182/blood-2003-01-01931 Even though ADAMTS13 protease determination has no immediate influence on the decision whether or not to start the plasma exchange therapy, it certainly has great impact on future dealings with the patient. As shown, if ADAMTS13 deficiency is found, the diagnosis of TTP has been proven with certainty, and we need not look any further trying to find causes of secondary TTP. Also, such a patient should be closely monitored for relapse and in the case of thrombocytopenia with elevated lactate dehydrogenase (LDH), plasma exchange therapy should be promptly started in order to avoid organ tissue damage. The purpose of presenting this case is to highlight how the absence of a severe ADAMTS13 protease deficiency does not preclude a diagnosis of TTP and how early initiation and continuation of plasma exchange therapy can lead to a positive outcome, even in a severely ill patient. Case Report The patient is a 61 year old female, with no other illnesses apart from hypertension, initially presented with symptoms of fever up to 400C, with chills, general poor condition and abdominal pain present for three days. She was then seen by an infectious disease physician. Initial work-up showed thrombocytopenia of 75 x 109/l, but no clinical findings indicated infectious etiology. She was referred to internal medicine specialist in an outside clinic. Platelet count at that point was 17 x 109/l, LDH was elevated. No anemia was present. She was conscious, but slow in response. During the next days non-oliguric acute renal failure developed. After platelet (PLT) substitution a kidney biopsy was performed and hemodialysis started. Histological examination showed extensive tubular damage with focal eccentric accumulation of hyaline material in walls of some artheriolas. These findings were indicative of TTP, so plasma exchange and steroids were initiated, and she was started on iv. antibiotics because of fever, although there were no sings of infection. Progression of alteration in mental status dominated the further clinical presentation, she became confused, altered, but without sings of focal damage, and CT scan was normal. Of note is, that the microimmunoflourescent test for antiplatelet antibodies was positive, both direct and indirect. The patient was then transferred to our intensive care unit for further treatment. Upon admission to our clinic her mental status had deteriorated, she was somnolent, reacting only to painful stimuli, with numerous hematoma on extremities. Blood pressure was somewhat higher 160/90 mmHg, pulse was 94/min, she was still febrile, although not over 38.4oC. Initial lab work-up showed leukocytosis with 7% of non-segmented granulocytes, moderate anemia (hemoglobin 110g/l, erythrocytes 3.55 x 109/l) with schistocytes on the peripheral blood smear, platelet count was 62 x 109/l. Serum creatinine was elevated (465 mmol/l), urea was 25.1 mmol/l, she had mild elevation of both conjugated and unconjugated bilirubin (16 mmol/l and 7 mmol/l , respectively) and of liver enzymes (AST 138 U/L, ALT 143 U/L, GGT 135 U/L). LDH was elevated (503 U/L), haptoglobin was within normal ranges (0.67g/l). Coombs test was negative. Fibrinogen degradation products were elevated (D-dimers were 5.34 mg/l) and fibrinogen decreased (1.8 g/l), with normal prothrombin time (0.9) and activated partial thromboplastin time (APTT) (28.2 s). C-reactive protein (CRP) was low, which was indicative of non-infectious origin of fever. Blood cultures were also done repeatedly, and were all negative. All other microbiological samples did not indicate infectious etiology, including cytomegalovirus (CMV) early antigen test. There was no evidence of malignant disease found. Initial immunology tests were done and showed no signs of autoimmune disease (antinuclear factor (ANF) negative, rheumatiod factor (RF) 9.75, anti-neutrophil cytoplasmic antibody (ANCA) negative, complement components tested were with in normal range). ADAMTS13 protease activity was determined and it was normal (64% and 60% activity), of note is that serum for testing was obtained after 2 sessions of plasma exchange had been done. Daily plasma exchange was continued, along with immunosuppressive therapy (methylprednisolone 80 mg iv. daily). Her condition did not improve during the first week; it actually worsened, hemoglobin level fell from >100 g/l to <60 g/l warranting packed erythrocyte transfusion, and her state of consciousness deteriorated. There was modest improvement around day 6 from admission, PLT count rose to >75 x 109/l, but improvement was transient. At that time she was conscious, but agitated, and transiently confused. There were hints of alcohol abuse, and alcohol withdrawal crisis was also considered. On day 12 the patient received 2mg of vincristine iv, to be continued in weekly applications. On day 19 PLT count was around 70 x 109/l, and around day 24, after the second application of vincristine, there was considerable improvement in PLT count (92 x 109/l), and plasma exchange procedure could be tapered. Around that time the patient started to feel better and her mental status improved. Treatment was continued with weekly vincristine injections, corticosteroids and plasma exchange therapy were tapered, and the state of the patient further improved (Figure 1). She was released on day 40 after admission, after receiving total of 27 plasma exchanges, and 5 weekly injections of vincristine (2mg/injection). Before release her PLT count was 169x109/l, hemoglobin was 79 g/l, Htc 0.241, creatinine 129 mmol/l, LDH 246 U/L. She continued with regular follow up visits, her hemoglobin level improved shortly after discharge, she did not need red blood cell substitution. In the follow up period of 2 years she had no relapses. Discussion and Conclusion Even though the pathogenesis of TTP is explained, and ADAMTS13 protease assay is widely available, we still rely predominantly on clinical symptoms when establishing the diagnosis of TTP. Nowadays, the pentad of symptoms is rarely encountered, and since early therapy initiation is crucial for therapy success, it is generally believed that evidence of microangiopathic hemolytic anemia (schistocytes, increased serum levels of lactate dehydrogenase, indirect bilirubin, and a negative direct Coombs test) and thrombocytopenia are sufficient to consider a diagnosis of TTP, particularly in the absence of signs and symptoms indicative of secondary cause, such as sepsis, malignant disease, pregnancy, or malignant hypertension (Table 1). Our patient had somewhat unusual initial presentation: abdominal pain, high fever with chills and thrombocytopenia without considerable anemia. When developed renal failure, physicians from an outside clinic performed kidney biopsy, not usually done to establish diagnosis of TTP, but it was still helpful. It was not until she was transferred to our intensive care unit that she became somnolent, and there were signs of intravascular destruction of platelets and Coombs-negative microangiopathic hemolytic anemia, which assured us it was a case of TTP. Misleading were the positive result of antiplatelet antibodies, and an anamnesis of high fever and chills, which are more indicative of infection, although all cultures taken were sterile, CRP was not elevated and there was no evidence of pneumonic infiltration or any other infection. We relied on clinical presentation and continued plasma exchange therapy; severe anemia that developed later only proved to our opinion the initial working diagnosis. Absence of a severe ADAMTS13 protease deficiency did not influence our diagnosis or our treatment plan; as it was shown not all patients with TTP have decreased ADAMTS13 protease activity and it should not be an exclusion factor in the diagnosis of TTP. Even though ADAMTS13 protease analysis was done after at least 2 plasma exchange sessions, we believe that this patient had no decreased ADAMTS13 protease activity, since generally more plasma exchange therapies are needed to eliminate antibodies and reinstitute metalloprotease activity ADDIN EN.CITE Bhm M2005181817Bhm M, Betz C, Miesbach W, et al The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristineBr J HaematolBr J Haematol644-652129200515. In conclusion, thrombotic thrombocytopenic purpura is a disease in which a considerable progress was made in deciphering the pathogenesis, improving therapy options and patients chances of survival. Today clinicians, when considering TTP as diagnosis, still mostly rely on the presence of thrombocytopenia and microangiopathic hemolytic anemia, and the absence of other causes for it. In the case of our patient we eliminated most of the more frequent causes for secondary TTP: malignant disease, pregnancy, toxic effect of drugs, systemic infection, and also could not prove that it was a case of idiopathic TTP. We do agree that ADAMTS13 deficiency determination is needed and necessary, and plasma should be taken for testing prior to starting plasma exchange therapy. Negative result does not exclude TTP diagnosis, but positive one reassures clinicians of their suspected diagnosis and is an important piece of information when planning future care for the patient in question. Acknowledgement: The authors would like to thank Dr. J. A. Kremer Hovinga, department of Hematology and Central Hematology Laboratory, Inselspital, Bern, Switzerland for measuring ADAMTS13 activity and for critical reading of the manuscript References: Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE, Blood, 102 (2003) 60. 2. Amorosi EL, Ultmann JE, Medicine, 45 (1966) 139. 3. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, N Engl J Med, 325 (1991) 393. 4. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lmmle B, N Engl J Med, 339 (1998) 1578. 5. Tsai HM, Lian EC, N Engl J Med, 339 (1998) 1585. 6. Fujikawa K, Suzuki H, McMullen B, Chung D, Blood, 98 (2001) 1662. 7. Gerritsen HE, Robles R, Lammle B, Furlan M, Blood, 98 (2001) 1654. 8. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM, Nature, 413 (2001) 488. 9. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C, J Bioche,130 (2001) 475. 10. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K, J Biol Chem, 276 (2001) 41059. 11. Gasparovic V, Radonic R, Mejic S, Pisl Z, Radman I, Intensive Care Med, 26 (2000) 1690. 12. Kremer Hovinga JA, Studt JD, Alberio L, Lmmle B, Semin Hematol, 41 (2004) 75. 13. Studt JD, Hovinga JA, Radonic R, Gasparovic V, Ivanovic D, Merkler M, Wirthmueller U, Dahinden C, Furlan M, Lmmle B, Blood, 103 (2004) 4195. 14. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP, Blood, 98 (2001) 1765. 15. Bhm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H, Scharrer I, Br J Haematol, 129 (2005) 644. 16. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pne F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B, Br J Haematol, 132 (2006) 66. 17. Tsai HM, Li A, Rock G, Clin Lab, 47 (2001) 387. 18. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE, Blood, 103 (2004) 4043. Corresponding author: Prof.dr.sc. V. Gaaparovi Department of Internal Medicine, Division of Intensive Care Medicine, Kiapatieva 12, 10000 Zagreb Tel: +385 98 276 388 E-mail:  HYPERLINK "mailto:vgasparovic111948@yahoo.com" vgasparovic111948@yahoo.com TROMBOTSKA TROMBOCITOPENI NA PURPURA  PRIKAZ SLU AJA TE`KO OBOLJELOG KOJI SE PREZENTIRAO NEOBI NOM KLINI KOM SLIKOM I NEGATIVNIM TESTOM ADAMTS13 PROTEAZE; ULOGA TESTA ADAMTS13 PROTEAZE U KLINI KOJ PRAKSI SA}ETAK Trombotska trombocitopeni na purpura (TTP) je bolest karakterizirana diseminiranin trombotskim okluzijama mikrocirkulacije. Identifikacija ADAMTS13 proteaze i njenog mjesta u patofiziologiji bolesti dovelo je do boljeg razumijevanja bolesti i boljeg pre~ivljenja oboljelih. Ovaj rad je prikaz slu aja bolesnica s normalnom razinom ADAMTS13 aktivnosti i neobi nom klini kom prezentacijom uz pomo kojega ~elimo naglasiti kako odsustvo teakog pomanjkanja ADAMTS13 aktivnosti ne izuzima dijagnozu TTP i kako rano zapo injanje i nastavak terapije izmjenom plazme mo~e dovesti do pozitivnog ishoda, ak i u teako oboljelih. Iako odreivanje nedostatka ADAMTS13  (,-=>FGOPWYZ  G H I J L T U V + 1 ϽϮ{m_m_mh)zWhpQ6]mH sH h)zWhq6]mH sH hq5\mHsHh F#5\mHsHhv5\mHsHh5\mHsH hahvhvh`h&QmHsHh`hvmHsH hah&Qh&Qh?5CJ \aJ mH sH h F#5CJ \aJ mH sH hv5CJ \aJ mH sH #XYZG H I J K L U V G H I J K $da$gdD 8dgdD 8dgdD 88 > G     G N [ \ Td !Ķīvnc[P[P[D<h#\emH sH jh?UmH sH hh?mH sH h?mH sH hD 8hD 8mH sH hmH sH h5\mH sH h&Q5\mH sH h)zWh&Q6]mH sH  h)zWh&Q56\]mHsHhq5\mHsHhD 8hD 86]mH sH "h)zWhDX*6]mH nHsH tHh)zWhDX*6]mH sH h)zWhq6]mH sH h)zWhD 86]mH sH K L M N [ \ ynooo@u}jk|\$d7$8$H$a$gdD 8$d7$8$H$a$gdzc $da$gd[ $da$gdD 8$d7$8$H$a$gd[dgdD 8 )*vwxy   'Ͽ۔۔۔ېxp`K(jh?B*UmH nHphsH tHh?B*mH nHphsH tHh?mHsHh$!h$!H*h#\ejh?UhD 8h?hh?mH nHsH tHh$!h$!H*mH nHsH tHh#\emH nHsH tHjh?UmH nHsH tHhD 8mH nHsH tHh?mH nHsH tHh$!h$!H*mH sH jh?UmH sH  !!!!!!!!!! " """C"L"M"00001ڶqeqUqh$!h$!H*mH nHsH tHh#\emH nHsH tHjh?UmH nHsH tHhD 8mH nHsH tHh?>*mH nHsH tHh?B*mH nHphsH tHh?mH nHsH tHhh?mH nHsH tH(h$!h$!B*H*mH nHphsH tH(jh?B*UmH nHphsH tHh#\eB*mH nHphsH tH111111122J2K22222"3#333344==>>>>G>?????FFFFG GGGHHSSSSSSGTPTXT庮ْكْْٺْْh?6]mH nHsH tHhvmH nHsH tHh$!h$!H*mH nHsH tHh#\emH nHsH tHjh?UmH nHsH tHh?5\mH nHsH tHh?mH nHsH tHhD 8mH nHsH tHhD 8hD 8mH nHsH tH3XTYTVVVVFWOWTWWWWW[[[[\\]]ffff#g(g)g7g8gggllll.l7lnnnnnnnynnǻǬǻǨǻǻǻǻyh?mH sH  hvhvh$!h$!H*h#\ejh[U h[h[ h[H*h[hh?mH nHsH tHhvmH nHsH tHh?mH nHsH tHh$!h$!H*mH nHsH tHh#\emH nHsH tHjh?UmH nHsH tH-nnnnno(o7ooooooooo&p'pRp[p`phpxpypppppppppNqcqeqfqqqqqqqqqrr#r+r9r}rrθh-h-mH sH hvmH sH h-mH sH hH*mH sH hxjmH sH hmH sH hkhmH sH h F#5\mH sH h5\mH sH hD 8mH sH h?mH sH hvmH nHsH tHhkh?mH sH 2rrrrr ss|s}sttttu vLvMvPvvvvvvvvvvvvvvw$w%w&w'w)w*wxx,x.xxxxxxxx¶zh[h[OJQJmH sH h[mH sH hD 8OJQJmH sH hD 8mH sH hH*mH sH hvmH sH h?h?H*mH sH h?mH sH hL mH sH h-mH sH hkmH sH hmH sH hkhmH sH hkhkmH sH 0xx y$y_zazqzrzzzzzzzzzz{S{T{{{{{{||C|||||||||||||||||}}}}}0}1}@}}麲ββΟʄhThvmHsHhTmHsHhvmHsHhThTmHsHhTmH sH h7mH sH hL mH sH hxjmH sH hvhvmH sH hD 8mH sH hkhmH sH hmH sH h[h[OJQJmH sH 4}}W~X~]~^~~~~~ Y\΀πЀрӀԀ׀ "/KLMNPQځ$%BNmtu}CDHRYZ*2JhzmH sH hTmH sH h[h[OJQJmH sH hhmH sH hmH sH hH*mH sH hvmH sH hD 8mH sH hmH sH hkhmH sH @JNԅ9B7I Eߊ \ƋۋopΌ!&/x؍ƾƲƔƔƈƲyyyhkhmH nHsH tHhImH nHsH tHhh?mH nHsH tHhhmH nHsH tHhmH nHsH tHhvmH sH h?mH nHsH tHh)zW5\mH sH h5\mH sH hmH sH hzmH sH hTmH sH ,%^gwYדCŔƔikͱ喇{o{cWcWchlmH nHsH tHh=0mH nHsH tHhn mH nHsH tHh?mH nHsH tHhh`0mH nHsH tHh`0mH nHsH tHh?hmH nHsH tHh$!h$!H*mH nHsH tHh#\emH nHsH tHjhpUmH nHsH tHhvmH sH hmH nHsH tHhhmH nHsH tHk|0[]kw(1ҙǻsdUUF:h|damH nHsH tHh#\eh|damH nHsH tHh|dah|damH nHsH tHh|dah#\emH nHsH tHh#\eh#\emH nHsH tHh#\emH nHsH tHh|dah$!mH nHsH tHh$!5\mH nHsH tHh[5\mH nHsH tHhmH nHsH tHhImH nHsH tHhDX*mH nHsH tHhhmH nHsH tH"hh5\mH nHsH tH\]^_`abcdefghijkw0d^`0gdD 8$ & FZd7$8$H$^Z`a$gd|da$d7$8$H$a$gd$!$d7$8$H$a$gdD 8Jbcdkš˚֚̚ךߚ 123;Rejmoqt>I[Ȝ۝Rtʷʷʷʕzh#\eh mH nHsH tHh mH nHsH tHh#\eh#\ehl?mH nHsH tHh#\eh#\emH nHsH tHhl?mH nHsH tH h#\eh#\eh#\emH nHsH tHh#\eh|damH nHsH tHh|damH nHsH tHh|dah#\emH nHsH tH-֞ڞrtvҠ"Dȶok\M\>h5CJ \aJ mHsHh F#5CJ \aJ mHsHh F#5CJ \aJ mH sH h F#+jh F#h F#UmH nHsH tH%jh F#h F#UmH nHsH tHh F#h F#mH nHsH tHh F#5\mH nHsH tH"h F#h F#5\mH nHsH tHhM5\mH nHsH tHh[mH nHsH tHh F#mH nHsH tHh|dah|da\mH nHsH tHڞԟdgdD 8dgdD 80d^`0gdD 8 ĠƠȠʠ̠ΠРҠnpxz|~ 0^`0gd? $dha$gd $da$gdD 8dgdD 80d^`0gdD 8Dlnp~vx {lZKZ 80% response to plasma exchange. Consider immunosuppressionSecondary TTPAssociated conditions include cancer, infection, hematopoietic stem cell transplantation, solid organ transplantation, SLE, chemotherapy, certain drugs (ticlopidin)Mechanisms are mostly unknown. ADAMTS13 deficiency is rare. With SLE severe ADAMTS13 deficiency describedNot likely to respond to plasma exchange therapy. Treatment and prognosis are dictated by the specific associated conditionsDiarrhea-associated HUS (D+HUS)Acute renal failure, preceded by bloody diarrhea.Endothelial damage by Shiga toxin producing E. coli. ADAMTS13 deficiency is rareNo demonstrated efficacy of plasma exchange.Atypical HUSAcute renal failure, no diarrheaComplement regulatory protein defects in at least 50% of patients; ADAMTS13 deficiency is rareNo demonstrated efficacy of plasma exchange, except possibly for factor H deficiency *Other than microangiopathic hemolytic anemia and thrombocytopenia, TTP  thrombotic thrombocytopenic purpura, HUS  Hemolytic-uremic syndrome, SLE  systemic lupus erythematosus, ADAMTS13 - a disintegrin and metalloprotease with thrombospondin type 1 repeats Fig. 1. Overwiev of therapy administered. PLT - platelets, Hb  hemoglobin, FFP  fresh frozen plasma, po  per os.     PAGE  PAGE 1 DnZ}kd$$Ifl\ |)z z z z 6`f)64 la$f&`#$/7$8$H$IfgdK$0^`0a$gdK BDlnhjVZtvdn6 024.2JL|JLͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻͻ(h6CJOJQJ]^JaJnHtH"hGLCJOJQJ^JaJnHtH"hUDCJOJQJ^JaJnHtH"hCJOJQJ^JaJnHtHhmH nHsH tH(h5CJOJQJ\^JaJnHtH"hKhK5\mH nHsH tH1jXZvf}kdn$$Ifl\ |)z z z z 6`f)64 laxx$f&`#$/7$8$H$IfgdK 40ffffxx$f&`#$/7$8$H$IfgdK}kd$$Ifl7\ |)z z z z 6`f)64 la02LLffffxx$f&`#$/7$8$H$IfgdK}kdd$$Ifl7\ |)z z z z 6`f)64 la xxhhhxxxxxx|dh7$8$H$^|gdGL dh7$8$H$}kd$$Ifl7\ |)z z z z 6`f)64 la (`dvzкp[OCOhUDmH nHsH tHhmH nHsH tH(hD 8hGLCJOJQJ^JaJnHtH(hGLhGLCJOJQJ^JaJnHtH6hD 8hGL6CJOJQJ]^JaJmH nHsH tH0hGLhGLCJOJQJ^JaJmH nHsH tH*hGLCJOJQJ^JaJmH nHsH tH"hGLCJOJQJ^JaJnHtH"hCJOJQJ^JaJnHtHhGLmH nHsH tH&hjpt 468:>@DFJLPR^`bfhtvxz|磔}y}y}y}yoioieoioZoieh`0JmHnHuh7) h7)0Jjh7)0JUh$(jh$(Uhn5CJ \aJ mH sH hK5CJ \aJ mH sH h5CJ \aJ mH sH hKhK6]mH sH hK6]mH sH 6hKhK6CJOJQJ]^JaJmH nHsH tHhKhK6]mHsHhK6]mHsH#  "$&(*,.0246gdK68<>BDHJNPbdf|~h]hgdq &`#$gdDX* 0^`0gdph5CJ \aJ mH sH hhKh7)h$(,1h/ =!"#$% DyK vgasparovic111948@yahoo.comyK Fmailto:vgasparovic111948@yahoo.comy$$If!vh5z 5z 5z 5z #vz :V l 6`f)65z 4y$$If!vh5z 5z 5z 5z #vz :V l 6`f)65z 4y$$If!vh5z 5z 5z 5z #vz :V l7 6`f)65z 4y$$If!vh5z 5z 5z 5z #vz :V l7 6`f)65z 4y$$If!vh5z 5z 5z 5z #vz :V l7 6`f)65z 4"666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH666666666666666666666666666666666666666666666666666666666666666666@@@ NormalCJ_HaJmH sH tH ^@"^ l Heading 2dd@&[$\$5CJ$\aJ$mH nHsH tHDA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k(No List 4U@4 Hyperlink >*ph3O Heading 22b$d%d&d'd-D`@&M NOPQ35B*CJOJQJ\^JaJmH nHphsH tHjOj Normal (Web)1xd ^x!B*CJaJmH nHphsH tH&O!& ti2CJaJ:O1: featured_linkouts&OA& linkbarlORl affiliation2xd x^x!B*CJaJmH nHphsH tH<B@b< Body Text5\mH sH *W@q* lStrong5\.X@. lEmphasis6]4 @4 qFooter  !.)@. q Page NumberR^@R F# Normal (Web)dd[$\$mH nHsH tHFV@F _FollowedHyperlink >*B* ph4O4 Oztxt,!importantBOB $!rprtbodydd[$\$mH sH 8O8 $!auxdd[$\$mH sH O $!src O $!jrnlXYZGHIJKLUVGHIJKLMN[\yfggg@mHtzzz[È45F&'()*+,-./012345A  !7Qʓ"#$%&'()*+,-./0123 WXYZ[\efҘܘݘPǙș֙{bc34Ab !"#$%&žÞ̞͞Ξٞڞ۞ܞޞ00000000000000000000000000000000000000000000000000000000000000 0000000000000000000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000000000000000000000000000000000000000L0000L000000000000L0000@0@000L00@ 0]L0L $$$' 1XTnrx}JkD TWYZ[\]^_`abcefisxy|K \06UXdghrtuvwz{V  ) vxL((,567>>@KKXLNNOSSU^^_ddUXғ QQQQQQQQQQQQQX  '!!l,2$s`ERڿ@0(  B S  ?1 ^1 D1 ̒1 4#1 1 ԙ1 $s1 >ɊɊϊ/͊ڊڊ59*urn:schemas-microsoft-com:office:smarttagsStateB*urn:schemas-microsoft-com:office:smarttagscountry-region8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsplace >&LTry#xTd';BOR b)p))).*7*=*J*** ffijijujj kllllknwnnn4o>oholooooo7pBppp&q4qrrrssss"s's1s2s=sHsLsNsVsXsbscssssttvv\wgwOxZxPy[yyyyyH|T|x||||AGW]afkry #*15RXfosz~Ɍ͌ӌٌ݌19y֍ڍߍ $*.48>CQU\afjtΎ׎%*7?DK[cimnr!")?DIPU\`jnvzӐܐ%)5=airzÑɑΑԑؑ $,;BGNRY]fowĒɒڒFPL͔۔ 56ѕҕij[]UƙoyckYa%56?@F˝ڝ &*+,.67OacžÞ۞ܞYZLTiizk|k~kkmmnnvvyy V\d&PžÞ۞ܞ33333333YZ#( 068>EK Y^5A2P֙4bPžÞ۞ܞžÞ۞ܞo62C,xj DSXr\DZhh҄" b11$YZԡNRE6Dh7"=KB1hyCqR=vcts,.u}8 ^`OJQJo(% ^`OJQJo(  pp^p`OJQJo(% @ @ ^@ `OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% PP^P`OJQJo(% ^`OJQJo("  ^`OJQJo("  pp^p`OJQJo("  @ @ ^@ `OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  PP^P`OJQJo("  ^`OJQJo( Q ^`OJQJo(  pp^p`OJQJo(  @ @ ^@ `OJQJo(  ^`OJQJo(  ^`OJQJo(  ^`OJQJo(  ^`OJQJo(  PP^P`OJQJo( 8^8`5o(. ^`hH.  L^ `LhH.  ^ `hH. x^x`hH. HL^H`LhH. ^`hH. ^`hH. L^`LhH. ^`OJQJo("  ^`OJQJo("  pp^p`OJQJo("  @ @ ^@ `OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  PP^P`OJQJo("  ^`OJQJo(%Q ^`OJQJo(  pp^p`OJQJo(% @ @ ^@ `OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% PP^P`OJQJo(% ^`OJQJo("  ^`OJQJo("  pp^p`OJQJo("  @ @ ^@ `OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  PP^P`OJQJo("  ^`OJQJo( Q ^`OJQJo(  pp^p`OJQJo(  @ @ ^@ `OJQJo(  ^`OJQJo(  ^`OJQJo(  ^`OJQJo(  ^`OJQJo(  PP^P`OJQJo( ^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`5o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH. ^`OJQJo(%Q ^`OJQJo(  pp^p`OJQJo(% @ @ ^@ `OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% PP^P`OJQJo(%^`o(. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH. ^`OJQJo(%Q ^`OJQJo(  pp^p`OJQJo(% @ @ ^@ `OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% PP^P`OJQJo(% ^`OJQJo(%Q ^`OJQJo(  pp^p`OJQJo(% @ @ ^@ `OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% ^`OJQJo(% PP^P`OJQJo(%^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo( ^`OJQJo("  ^`OJQJo("  pp^p`OJQJo("  @ @ ^@ `OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  ^`OJQJo("  PP^P`OJQJo(" KBqRvcj 1Zhhu}C,YZo6sNRh7yCSXr%^hENf JjV!/6ʞb^F.q'OԂLuVVje.'!~`S#"FlRT         .V dZ͚Tʩxv NaF)d<Enabled>1</Enabled><ScanUnformatted>1</ScanUnformatted><ScanChanges>1</ScanChanges></ENInstantFormat>W<ENLayout><Style>Circulation</Style><LeftDelim>{</LeftDelim><RightDelim>}</RightDelim><FontName>Times New Roman</FontName><FontSize>12</FontSize><ReflistTitle></ReflistTitle><StartingRefnum>1</StartingRefnum><FirstLineIndent>0</FirstLineIndent><HangingIndent>720</HangingIndent><LineSpacing>0</LineSpacing><SpaceAfter>0</SpaceAfter></ENLayout>F<ENLibraries><Libraries><item>TTP.enl</item></Libraries></ENLibraries>@YY YYpQoQpyzʒʓʔp@pxp@pp @ppppUnknownGz Times New Roman5Symbol3& z Arial5& zaTahoma] StarSymbolTimes New RomanO& k9?Lucida Sans Unicode?5 : Courier New;Wingdings"1h@cf@cfӲ&Q Q !4dff2QHX?@2XThrombotic thrombocytopenic purpura  how usefull is ADAMTS13 assay in clinical practiceNadira Durakovic, MDkbcL           Oh+'00<HX dp    \Thrombotic thrombocytopenic purpura how usefull is ADAMTS13 assay in clinical practiceNadira Durakovic, MDNormalkbc2Microsoft Office Word@F#@Y@?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}Root Entry FVIPData ~1TablemWordDocument.SummaryInformation(DocumentSummaryInformation8CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q